Ireland's Elan Corp says it has entered into an agreement toacquire Carnrick Laboratories, a privately-owned pharmaceutical firm, from parent company GWC Health. Elan will pay $150 million in a combination of cash and promissory note. The transaction, which will be earnings-neutral to Elan this year, is expected to close in the second quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze